| HS Code | 819336 |
| Product Name | Talc Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Cas Number | 14807-96-6 |
| Molecular Formula | Mg3Si4O10(OH)2 |
| Molecular Weight | 379.27 g/mol |
| Appearance | Fine white to off-white, unctuous, crystalline powder |
| Odor | Odorless |
| Solubility | Practically insoluble in water, ethanol, dilute acids, and dilute alkalis |
As an accredited Talc Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Sealed drums with tamper-evident polyethylene liners, 25 kg net, labelled for veterinary API use in tablets, injections, capsules, powders, granules, premix, solutions. |
| Container Loading (20′ FCL) | 20′ FCL loaded with palletized, secured drums/containers of Talc Veterinary Grade API, ensuring safe transport and stability. |
| Shipping | Talc Veterinary Grade API is shipped in sealed, moisture-protected containers (drums or bags) with secure palletization. Transport via dry, ventilated freight to prevent contamination. Avoid high humidity, direct heat, and incompatible materials. Standard handling with dust masks and gloves; non-hazardous under normal shipping conditions. |
| Storage | Store Talc Veterinary Grade API in a tightly sealed, original container in a cool, dry, well-ventilated area, away from direct sunlight and moisture. Maintain room temperature (15–30°C). Protect from dust and contamination. Keep separate from strong oxidizers and acids. Ensure container is closed after each use to preserve quality. |
| Shelf Life | Shelf Life: 36 months from manufacture date when stored in original, tightly closed container in a cool, dry place. |
In medicated feed premix lines, talc veterinary grade is introduced as a hydrophobic anticaking agent and flow regulator at 0.5 wt% to 3.0 wt% of the premix batch. The addition level is determined by the hygroscopic load of the formulation: premixes containing choline chloride, ferrous sulphate monohydrate, or vitamin AD3E powders generally require the upper portion of the range, while zinc oxide and dicalcium phosphate blends tolerate the lower portion. The talc grade should comply with Ph. Eur. 0438 and the USP Talc monograph for asbestos absence, and the feed-use status is governed by Regulation (EC) No 1831/2003 as technological additive E553b in the anticaking functional group. Downstream production is carried out in horizontal plow mixers or double-ribbon blenders with batch residence times of 3–8 minutes and tip speeds below 1.5 m/s; intensive high-shear mixing above this speed can generate electrostatic wall fouling, reducing talc availability at the powder surface. The resulting premix is diluted with ground maize or wheat middlings at 2–5 kg per tonne of complete feed, passed through a centrifugal sifter with 0.8–1.2 mm mesh, and packed in multi-wall paper sacks or flexible bulk containers. Terminal finished product types include vitamin-mineral premixes for poultry, swine, and ruminant rations, coccidiostat and anthelmintic in-feed oral powders, and dry carrier premixes for non-medicated nutritional additives.
During bulk storage and pneumatic conveying, caking failures are most common when the talc particle size distribution shifts above 20 µm D90, because coarse talc segregates from fine active carriers and no longer coats contacting hygroscopic surfaces. The silo discharge pattern should be mass flow rather than funnel flow; funnel flow geometries allow preferential channeling of talc-coated fines and can leave stagnant regions where choline chloride and trace minerals hydrate. Talc does not chemically bind moisture like silica gel, so it is not a substitute for sealed packaging or storage at 20–25°C and relative humidity below 60%. In premixes with organic acids or acidic transition-metal salts, compatibility should be confirmed by accelerated stability studies at 40°C / 75% RH because talc can adsorb certain protonated species, altering surface pH equilibrium; published data for specific acidic premix configurations is limited.
In direct compression of veterinary oral tablets and large-animal boluses, talc is added as an anti-adherent and glidant at 1.0 wt% to 5.0 wt% of the formulation. The lower end of the range is usually sufficient for free-flowing granulations, whereas wet-granulated materials with residual moisture between 1.5% and 2.5% and high fine-particle load require 3.0–5.0 wt% to prevent build-up on punch tips and die bores. Talc should be blended in a bin blender or V-blender for 10–15 minutes before magnesium stearate is added; this sequence prevents the hydrophobic talc platelet film from coating the lubricant and altering its shear boundary function. On rotary tablet presses operating above 60 rpm, a talc level below 1.0 wt% is associated with increased ejection force and audible punch squeal, particularly on high-speed machines without forced feeder spray lubrication. The grade must meet Ph. Eur. 0438 and USP Talc monograph controls, including absence of amphibole asbestos by X-ray diffraction or infrared methods, and elemental impurity limits under ICH Q3D as adopted in the relevant veterinary pharmacopoeial monograph. Terminal finished product types include chewable anthelmintic tablets for dogs, non-steroidal anti-inflammatory tablets for cats and dogs, calcium/phosphorus boluses for ruminants, and sustained-release rumen boluses.
Exceeding 5.0 wt% talc can reduce tablet tensile strength and prolong disintegration because the lamellar magnesium silicate platelets interrupt interparticulate bonding between active granules. For bolus formulations compressed at higher unit weights, the talc fraction is often held at 2.0–3.0 wt% to balance anti-adherent performance against friability control; friability should be tested according to Ph. Eur. 2.9.7 or USP <1216>, and disintegration according to Ph. Eur. 2.9.1 or USP <701>. The production-scale bottleneck is not mixing but press dwell time: talc layers may reduce ejection friction by up to 20–30% under appropriately set compression force, but if the main compression force exceeds the formulation’s plastic deformation threshold, the talc film can be fractured and metal-to-powder contact re-established. Therefore, compression profiles should be recorded with instrumented press data, and punch tip lubricity should be monitored by lower punch ejection force rather than visual inspection alone.
Talc is incorporated into low-dose hard gelatin capsule powder blends at 1.0 wt% to 3.0 wt% as a glidant and anti-caking agent, particularly where the active pharmaceutical ingredient is present below 5 mg per capsule and requires lactose monohydrate or microcrystalline cellulose as the bulking diluent. In dosator and tamping-pin capsule fillers running at 20,000–150,000 capsules/hour, the addition of talc reduces powder adhesion to compression dies and dosing sleeves, improving plug weight uniformity and reducing reject rates caused by powder sticking. The grade must comply with Ph. Eur. 0438 for talc and the microbial limits of Ph. Eur. 2.6.12 and 2.6.13, because capsule fill is a non-sterile oral process but must meet bioburden acceptance criteria before packaging. The blend is passed through a 0.5–1.0 mm conical mill or screen after blending to break up talc agglomerates that can otherwise yield inconsistent capsule fill weights. Terminal finished product types include antibiotic capsules for companion animals, proton-pump inhibitor capsules for equine gastric ulcer therapy, and low-dose parasiticides in hard gelatin capsules.
The main batch-to-batch variance in encapsulation is electrostatic charging of talc during low-humidity operations below 30% RH. Under such conditions, talc-coated lactose blends may develop surface charge that reduces flowability despite the glidant, and the capsule filler may require humidification to 40–50% RH or the use of ionizing bars. Because talc is hydrophobic, it does not dissolve during dissolution testing; at levels above 3.0 wt%, it can form a hydrophobic film on hydrophilic fillers and slow drug release from the open capsule mass. Dissolution should be evaluated using Ph. Eur. 2.9.3 or USP <711> in the intended species-relevant buffer, and capsule disintegration according to Ph. Eur. 2.9.1. Talc is not a substitute for a true lubricant in capsule filling; formulations that show plug ejection difficulties at high fill speeds may require a separate hydrophobic lubricant or a reduced talc level, not an increase beyond the stated range.
In wet granulation suites producing medicated oral granules and sachet powders, talc is added after fluid-bed drying as an anti-tacking and flow-control agent at 1.0 wt% to 4.0 wt% of the dried granule mass. The addition point is critical: if talc is incorporated during the wet massing stage in a high-shear mixer, it can become trapped inside porous granules and raise disintegration time without reducing surface tack, so the preferred route is post-drying blending in a bin blender or gentle tumbling mixer followed by screening through an oscillating granulator equipped with a 0.8–1.2 mm mesh. The talc grade should meet Ph. Eur. 0438, and the granule production should be performed under EU GMP Part I or equivalent veterinary GMP with documented cleaning validation for talc residues on contact surfaces. Terminal finished products include oral granules for in-feed or drinking-water administration, electrolyte granules for calf and piglet rehydration, and probiotic or enzyme granules packaged in aluminum-laminated sachets.
Fluid-bed drying endpoints are determined by loss-on-drying, and the operational window is typically 1.5–2.5% residual moisture; if the outlet air temperature or dew point control fails and granule moisture exceeds 12% during upset conditions, talc cannot correct the resulting surface adhesion and the batch should be re-dried before post-blending. A secondary failure mode is over-screening: passing talc-blended granules through a screen below 0.5 mm can generate fines that segregate to the bottom of the sachet and reduce content uniformity. The batch uniformity of sachet fill is assessed by mass and content uniformity according to Ph. Eur. 2.9.40 or Ph. Eur. 2.9.5, and the talc fraction contributes to the inert insoluble portion that is visible upon reconstitution; if the final granule is intended for clear oral solution, talc should not be used because its sedimentation is irreversible and will produce a cloudy supernatant.
In multi-dose oral liquid preparations for veterinary use, talc is used as an opacifier and physical stabilizer at 1.0% w/v to 5.0% w/v, but it is not a primary suspending agent. The talc platelets contribute opacity and cover the appearance of suspended drug particles, yet they settle rapidly in aqueous media unless a structured vehicle such as xanthan gum, microcrystalline cellulose/sodium carboxymethylcellulose, or bentonite is present at appropriate rheological concentrations. The talc grade must comply with Ph. Eur. 0438 and the non-sterile oral liquid microbial standards of Ph. Eur. 5.1.4 or USP <1111>; it should also meet the elemental impurity requirements of ICH Q3D because the product is administered repeatedly to food-producing animals. The liquid is prepared by high-shear dispersion of talc in a portion of the aqueous phase containing a wetting agent, followed by incorporation into the main batch under low-shear agitation, then homogenization at 5–10 m/s rotor-stator tip speeds and filling into amber HDPE bottles or multi-dose dispensing containers. Terminal finished products include oral suspensions of anthelmintics for sheep and cattle, oral drench suspensions for poultry, and oral pastes or pump-dispensed suspensions for swine.
The critical operating boundary is sedimentation bed compaction: at talc levels above 5.0% w/v, settled sediment can form a hard cake that does not redisperse with moderate shaking, leading to under-dosing in the final poured volume. The redispersibility should be tested according to Ph. Eur. 2.9.36 or equivalent quality control methods, using a defined number of inversion cycles. Talc is incompatible with strong acid vehicles below pH 2 over long storage because magnesium ions can leach into solution and alter the ionic strength of the structured vehicle; compatibility at the intended pH and storage temperature should be confirmed by real-time stability studies. The product should not be filled without continuous agitation, because talc settles quickly in low-viscosity liquids; fill lines without recirculating or stirred hold tanks may show a progressive increase in talc concentration from the beginning to the end of the fill run.
Talc for injectable or intrapleural use is a separate application from oral and feed uses. In small animal practice, sterile talc slurry is occasionally prepared for chemical pleurodesis in dogs and cats with recurrent pleural effusion, but regulatory approval and published veterinary-specific dosing data are limited. The preparation is not a conventional solution; talc is insoluble and is suspended in injectable 0.9% w/v sodium chloride at a concentration equivalent to 4–5 g in 50 mL in human protocols, and the same concentration range has been reported in small case series. The talc grade must be sterilized by dry heat at 160°C for 2 hours or by gamma irradiation, because moist-heat terminal sterilization of talc slurry causes aggregation and caking. Sterility should be confirmed by Ph. Eur. 2.6.1 or USP <71>, bacterial endotoxins by Ph. Eur. 2.6.14 or USP <85>, and particulate matter limits should follow the intended route-specific risk assessment. Terminal finished product type is a single-use intrapleural slurry for instillation through a chest drain; the slurry must not be administered intravenously, intramuscularly, or subcutaneously.
The production process for this presentation is performed under grade A aseptic conditions within a grade B suite according to EU GMP Annex 1, with the dry talc sterilized and then transferred aseptically to sterile saline in a closed system. The slurry must be agitated gently before instillation to avoid sedimentation; if the suspension is allowed to stand for more than 2–3 minutes, talc will settle and the instilled dose will be non-uniform. Because talc for intrapleural use is a drug product rather than an excipient, the batch documentation must include chemical identity, absence of asbestos, elemental impurities, sterility, endotoxin, and particulate load. Published data for this specific veterinary configuration is limited, and use should be restricted to specialist veterinary centers with the necessary imaging, chest drain placement, and adverse-event management capabilities. No additional excipient addition ratio applies; the entire sterile talc content is the active sclerosing agent, and dilution volumes should not be altered without stability and sterility verification.
Competitive Talc Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Talc Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied under three controlled model codes. TVG-200P is a direct-compression and granulation-grade lamellar magnesium silicate; TVG-500M is a micronized product for suspension, non-intravenous injectable, and low-dose premix applications; TVG-800R is a coarser premix and free-flow grade. The product conforms to the talc monograph of Ph. Eur. 0438 and aligns with USP-NF Talc. Although “API” appears in the commercial descriptor, talc is not an active pharmaceutical ingredient; it is a mineral excipient. The powder is white to grey-white, odourless, greasy to the touch, and practically insoluble in water, ethanol, dilute acids, and dilute alkalis. In the context of the product title, “Solutions” refers to non-intravenous suspension intermediates and process aids, not to dissolved talc.
Talc is a naturally occurring hydrated magnesium silicate of approximate formula Mg3Si4O10(OH)2. Accessory minerals such as chlorite, magnesite, dolomite, and quartz may be present in raw ore; pharmacopoeial tests for magnesium, aluminium, calcium, iron, acid-soluble substances, and loss on ignition constrain these accessory components. Because the raw material is mined rather than synthesized, batch-to-batch variance is controlled by ore selection, magnetic separation, milling, and terminal blending rather than by chemical synthesis. In veterinary tablets and capsules, the primary functions are glidant, anti-adherent, and anti-caking agent. In powders and premixes, the material provides free flow and moisture-independent anti-caking. In granules, it reduces picking and sticking during compression. For non-intravenous injectable suspensions, it is an insoluble dispersed solid that must meet particulate and endotoxin controls.
The product is manufactured only from selected talc ore; it is not a surface-treated or organophilic grade. The absence of surface treatment is important because silane-treated or aminosilane-coated talc used in polymer composites is not acceptable for veterinary dosage use. The hydrophobic character of untreated talc arises from its lamellar basal surfaces, not from added water repellents.
Technical talc sourced for ceramics, plastics, and coatings is not suitable for veterinary dosage manufacture because ore lots may contain variable levels of tremolite, anthophyllite, crystalline silica, and heavy metals. Cosmetic talc is controlled for microbiological and selected metal limits but is not routinely released against acid-soluble substances, loss on ignition, or injection-particulate requirements. Food-grade talc E553b is not automatically supported by a pharmacopoeial certificate of analysis and may have a different top-size distribution or higher residual iron and aluminium burden. The veterinary-grade product is controlled as an excipient from mineral origin with route-specific release criteria.
| Material category | Control benchmarks | Principal limitation |
|---|---|---|
| Technical talc | ISO 3262 type specifications; no pharmacopoeial release | Variable tremolite, anthophyllite, crystalline silica; unsuitable for veterinary dosage |
| Cosmetic talc | EC 1223/2009; microbiological limits | No acid-soluble, loss-on-ignition, or injection-particulate controls |
| Food-grade talc E553b | JECFA/food additive purity criteria | May not meet pharmaceutical heavy metal, endotoxin, or microbial strain controls |
| Veterinary/pharmaceutical talc | Ph. Eur. 0438, USP-NF Talc, ICH Q3D, optional USP <788>/USP <85> | Requires route-specific validation and segregation of sterile/nonsterile models |
The practical effect of these differences appears in production. Industrial talc may contain asbestos-form fibres that are not reduced by ordinary blending; pharmacopoeial talc must be free of detectable tremolite and anthophyllite by the methods prescribed in the monograph. The veterinary grade also carries a documented chain of custody from crushing, magnetic separation, micronization, and terminal blending. Because natural talc deposits vary in accessory minerals, the certificate of analysis should include magnesium, aluminium, calcium, iron, loss on ignition, acid-soluble substances, and microbiological limits for each batch. Substitution of cosmetic or food lots based on visual similarity is not technically valid for veterinary dosage manufacture.
The compendial talc monograph is the baseline. Ph. Eur. 0438 does not specify a single particle-size limit, so the product models carry vendor-specific particle-size and surface-area bands that must be justified in the formulation dossier. These bands are measured by laser diffraction according to ISO 13320-1:2020. The following table summarizes the principal chemical, physical, and microbiological release parameters for the veterinary-grade powder. Values are taken from the current pharmacopoeial monograph where applicable; route-specific particulate and endotoxin controls are additional.
| Quality attribute | Acceptance criterion | Method or standard |
|---|---|---|
| Magnesium content | 17.0% to 20.0% | Ph. Eur. 0438 |
| Loss on drying | ≤ 0.5% | Ph. Eur. 2.2.32 / USP <731> |
| Loss on ignition | ≤ 7.0% | Ph. Eur. 0438 |
| Acid-soluble substances | ≤ 2.0% | Ph. Eur. 0438 |
| Iron | ≤ 0.25% | Ph. Eur. 0438 |
| Aluminium | ≤ 2.0% | Ph. Eur. 0438 |
| Calcium | ≤ 0.9% | Ph. Eur. 0438 |
| Heavy metals | ≤ 20 ppm | Ph. Eur. 0438 |
| pH of aqueous suspension | 7.0–10.0 | Ph. Eur. 0438 |
| Non-sterile microbial quality | 103 CFU/g TAMC, 102 CFU/g TYMC, E. coli absent | Ph. Eur. 5.1.4 / USP <1111> |
Elemental impurity control follows ICH Q3D; route-specific limits for lead, arsenic, cadmium, and mercury are assessed against permitted daily exposure values. The heavy metal test is not sufficient for injectable-grade justification; USP <232>/USP <233> or equivalent validated inductively coupled plasma-mass spectrometry methods are expected.
Model-specific particle-size specifications are the main release distinction from general talc. TVG-200P is fine-milled; TVG-500M is jet-mill micronized; TVG-800R is a low-dust premix grade. Particle size is measured by laser diffraction using ISO 13320-1:2020. Dry dispersion requires controlled air pressure because over-dispersion can split talc plates along cleavage planes and increase the apparent fines fraction. Wet dispersion may require sodium hexametaphosphate or a non-ionic wetting agent. Surface area is measured by nitrogen adsorption according to ISO 9277:2010; a surface-area shift across batches can indicate milling or ore-source changes even when the median particle size remains stable. For low-dose actives, increased surface area may increase adsorption to the talc surface and should be evaluated by content uniformity and dissolution testing using USP <905> and USP <711> / Ph. Eur. 2.9.3.
Bulk density and tapped density are measured using USP <616> / Ph. Eur. 2.9.34. Talc has a low bulk density; the micronized model segregates more readily than the premix model. Transfer systems with long drop heights or vibrating chutes can stratify the blend, producing low-potency or high-potency fractions in the hopper. Closed vacuum transfer and short drop heights are used for direct compression and encapsulation lines. Powder flow is determined by USP <1174>; because talc is hydrophobic, flow can remain high at low moisture but may become static-charged in dry environments. Static-charge buildup on plastic transfer tubing can cause adhesion to walls; grounding and ionized air are standard corrective measures.
Talc is practically insoluble and should not be presented as a true solution. Injectable use is limited to non-intravenous suspension formulations or to manufacturing aids that are subsequently removed by filtration. In such presentations, the oral-grade release is not sufficient. The injectable-grade model TVG-500M is tested for bacterial endotoxins using USP <85> / Ph. Eur. 2.6.14, subvisible particulate matter using USP <788> / Ph. Eur. 2.9.19, and sterility where a sterile claim exists using USP <71> / Ph. Eur. 2.6.1. Particle-size distribution is tightened to reduce the risk of large lamellar clusters; because talc platelets can orient under pumping shear, the suspension must be evaluated for aggregation after 24 h and after gentle agitation. Terminal dry-heat sterilization is physically feasible because talc tolerates high temperature, but container moisture and headspace humidity must be controlled to avoid particle adhesion. Gamma irradiation may be less suitable if it generates surface radicals that alter zeta potential; published data for this specific configuration is limited.
For injectable-grade talc, particle counts are tested using light obscuration after dispersion in a suitable vehicle. The test is not a cosmetic or feed-grade procedure; it is derived from injectable suspension requirements. The acceptance criteria are set by the formulation developer and are not provided in the pharmacopoeial talc monograph.
On tablet lines, the anti-adherent function is effective at 1.0–3.0% w/w. Talc should be added in the final blending step after magnesium stearate or as an external phase. If added before the lubricant, talc can coat granules and reduce tablet tensile strength. Tablet hardness is measured by USP <1217> / Ph. Eur. 2.9.8; friability is measured by USP <1216> / Ph. Eur. 2.9.7. In direct compression, 1.0% w/w talc may be sufficient to prevent sticking on rotary presses, but 3.0% w/w may reduce friability at the cost of hardness. Capsule filling with low-dose actives requires 0.5–2.0% w/w talc as a flow aid; higher levels can reduce powder-plug density and alter dissolution. The hydrophobic surface can retard wetting of poorly soluble actives, so dissolution screening with USP <711> / Ph. Eur. 2.9.3 should be performed when talc is above 2.0% w/w.
On high-speed encapsulation machines, talc may be used as a dusting powder on capsule shells to prevent sticking in transport rails, but only if the grade has been tested for particle-size control and microbial limits. The dusting application should be considered an excipient addition, not a processing aid, and should appear in the batch formula. For tablet pan coating, talc can be used as an anti-tacking agent in aqueous film-coating suspensions; because talc is insoluble, it must be well dispersed and continuously stirred to prevent sedimentation. The use level in coating dispersions is typically 1.0–3.0% of the coating liquid mass, but actual levels depend on polymer concentration and coating pan efficiency.
In wet granulation, talc is preferably added after drying because the hydrophobic platelet surface can reduce binder wetting if introduced before the granulating fluid. In roller compaction, talc reduces sticking to rolls but may increase ribbon lamination if fines are too high; roll gap and hydraulic pressure should not be adjusted to compensate for poor blend flow without remeasuring particle-size distribution. In powder blends for sachets and dry powders, talc at 1.0–5.0% w/w reduces caking and improves flow. If the powder is exposed to cyclic humidity, the moisture-independent nature of talc provides technical utility over hygroscopic anti-caking agents, but it does not protect the active ingredient from moisture; a desiccant package or moisture barrier is still required when the active is labile.
Because talc is a mined mineral, incoming lots may contain spore-forming bacteria, yeasts, moulds, and environmental metals. Non-sterile veterinary grades are released against Ph. Eur. 5.1.4 criteria; objectionable organisms are absent from the model designation. The absence of Escherichia coli, Salmonella, Staphylococcus aureus, and Pseudomonas aeruginosa is specified for non-sterile oral and premix grades. For injectable suspension grades, the product is not considered sterile as supplied; it is labelled as a sterile-process intermediate or is sterilized downstream. Environmental monitoring and air classification during micronization are used to control bioburden, because mineral powders cannot be filtered or sterilized by moist heat without forming cakes. Dry heat is the most compatible sterilization method, but the temperature and time cycle must be validated for the container load and talc bed depth.
In terms of elemental impurities, talc contributes silicon, magnesium, aluminium, iron, and calcium as part of its crystal lattice. Lead, arsenic, cadmium, and mercury are controlled because they may derive from accessory sulphides or carbonates. A formal ICH Q3D risk assessment should be completed for each route of administration; oral and parenteral permitted daily exposure values differ by orders of magnitude.
Regulatory acceptance of talc in veterinary medicines follows the pharmacopoeial monographs. The product is supplied with a certificate of analysis, certificate of origin, BSE/TSE-free statement, residual solvent statement, elemental impurity statement, and a description of the manufacturing process. The product is of mineral origin and does not present TSE risk. Mining and processing do not use animal-derived materials. For EU/EEA submissions, Ph. Eur. 0438 is the primary standard; for US submissions, USP-NF Talc, ICH Q3D, and route-specific microbiological chapters are referenced. The term “API” in the commercial name should be clarified in regulatory documents as an excipient designation; this prevents misclassification in dossiers and avoids incorrect stability or bioequivalence requirements.
Veterinary premixes and medicated feeds may contain talc as a free-flow aid at inclusion rates up to 5.0% w/w. The material is chemically inert in dry feed matrices but can separate from granular carriers during transport. Mixing studies generally use a tracer coefficient of variation below 5.0% across multiple sampling points; silicon or magnesium can be quantified by inductively coupled plasma-optical emission spectrometry as a marker. For solution preparations, talc cannot be used as a dissolved component. It may be included as a dispersion aid in dry powders for reconstitution into oral suspensions, where it remains suspended and contributes negative surface charge at neutral pH. Cationic polymers can induce flocculation; compatibility testing with buffers and preservatives is required. Talc is stable under normal veterinary manufacturing conditions but is not a buffering agent and should not be combined with strong oxidising agents or mineral acids without compatibility testing. For direct-compression lines running at 60–90 rpm, punch polishing and clean compressed air at the die table reduce build-up on tooling when talc levels are kept at the low end of the validated range.
